Pfizer expects to petition the Food and Drug Administration for authorization of its coronavirus vaccine by the third week of November after early clinical trial results showed its efficacy as high as 90%.

“Today is a great day for science and humanity,” Dr. Albert Bourla, Pfizer chairman and CEO, said on Monday. “With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.”